Abstracts tagged "tocilizumab and giant cell arteritis"

Abstract Number: 808 • ACR/ARP Annual Meeting 2019
Long-Term Outcome of Tocilizumab for Patients with Giant Cell Arteritis: Results from Part 2 of a Randomized Controlled Phase 3 Trial
John Stone¹, Min Bao ², Jian Han ², Martin Aringer ³, Daniel Blockmans ⁴, Elisabeth Brouwer ⁵, Maria C. Cid ⁶, Bhaskar Dasgupta ⁷, Jürgen Rech ⁸, Carlo Salvarani ⁹, Robert Spiera ¹⁰ and Sebastian Unizony ¹, ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Genentech, South San Francisco, CA, ³Division of Rheumatology, Department of Medicine III, University Medical Center & Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany, Dresden, Germany, ⁴Department of General Internal Medicine, University Hospitals Gasthuisberg, Leuven, Belgium, ⁵Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁶Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain, ⁷Southend University Hospital, NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, ⁸Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany, ⁹Division of Rheumatology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, ¹⁰Hospital for Special Surgery, New York, NY
Background/Purpose: Tocilizumab (TCZ) 162 mg administered subcutaneously weekly (QW) or every-other-week (Q2W) plus 26-wk prednisone tapering resulted in higher rates of sustained glucocorticoid (GC)–free remission…
Abstract Number: 1838 • ACR/ARP Annual Meeting 2019
Time to Flare in Patients with New-Onset versus Relapsing Giant Cell Arteritis Treated with Tocilizumab or Placebo Plus Prednisone Tapering: 3-Year Results from a Randomized Controlled Phase 3 Trial
John Stone¹, Helen Spotswood ², Sebastian Unizony ¹, Martin Aringer ³, Daniel Blockmans ⁴, Elisabeth Brouwer ⁵, Maria C. Cid ⁶, Bhaskar Dasgupta ⁷, Jürgen Rech ⁸, Carlo Salvarani ⁹, Robert Spiera ¹⁰ and Min Bao ¹¹, ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Roche Products, Ltd., Welwyn Garden City, United Kingdom, ³Division of Rheumatology, Department of Medicine III, University Medical Center & Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany, Dresden, Germany, ⁴Department of General Internal Medicine, University Hospitals Gasthuisberg, Leuven, Belgium, ⁵Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁶Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain, ⁷Southend University Hospital, NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, ⁸Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany, ⁹Division of Rheumatology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹Genentech, South San Francisco, CA
Background/Purpose: Tocilizumab (TCZ) administered subcutaneously every week (QW) or every other week (Q2W) with 26-week prednisone tapering was superior to placebo (PBO) plus 26-week (PBO+26)…
Abstract Number: 1840 • ACR/ARP Annual Meeting 2019
Risk Factors for Treatment Failure in Patients with Giant Cell Arteritis Treated with Tocilizumab Plus Prednisone versus Prednisone Alone
Sebastian Unizony¹, Min Bao ², Jian Han ², Yves Luder ³, Páris Sidiropoulos ², Jinglan Pei ² and John Stone ¹, ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Genentech, South San Francisco, CA, ³F. Hoffmann-La Roche, Basel, Switzerland
Background/Purpose: Risk factors for treatment failure in patients with giant cell arteritis (GCA) are poorly understood. The objective of this analysis was to identify predictors…
Abstract Number: 2663 • ACR/ARP Annual Meeting 2019
Maintained Benefit in Health-Related Quality of Life of Patients with Giant Cell Arteritis Treated with Tocilizumab Plus Prednisone Tapering: Results from the Open-Label, Long-Term Extension of a Phase 3 Randomized Controlled Trial
John Stone¹, Jian Han ², Sebastian Unizony ¹, Martin Aringer ³, Daniel Blockmans ⁴, Elisabeth Brouwer ⁵, Maria C. Cid ⁶, Bhaskar Dasgupta ⁷, Jürgen Rech ⁸, Carlo Salvarani ⁹, Robert Spiera ¹⁰ and Min Bao ², ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Genentech, South San Francisco, CA, ³Division of Rheumatology, Department of Medicine III, University Medical Center & Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany, Dresden, Germany, ⁴Department of General Internal Medicine, University Hospitals Gasthuisberg, Leuven, Belgium, ⁵Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ⁶Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain, ⁷Southend University Hospital, NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, ⁸Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany, ⁹Division of Rheumatology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, ¹⁰Hospital for Special Surgery, New York, NY
Background/Purpose: Patients with giant cell arteritis (GCA) treated with tocilizumab (TCZ) plus prednisone tapering achieved higher rates of sustained glucocorticoid (GC)-free remission and had lower…